452 related articles for article (PubMed ID: 7502559)
1. [Comparison between tacrolimus (FK 506) and cyclosporin in immunosuppressive therapy after liver transplantation].
Arnold JC; Theilmann L
Z Gastroenterol; 1995 Oct; 33(10):624-5. PubMed ID: 7502559
[No Abstract] [Full Text] [Related]
2. Tacrolimus (FK 506) therapy is associated with a significant reduction in immunosuppressive treatment failures following primary liver transplantation.
Bechstein WO; Neuhaus P; McMaster P; Calne R; Pichlmayr R; Otto G; Williams R; Ericzon BG; Bismuth H
Transplant Proc; 1996 Apr; 28(2):1008-10. PubMed ID: 8623211
[No Abstract] [Full Text] [Related]
3. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
[No Abstract] [Full Text] [Related]
4. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
[No Abstract] [Full Text] [Related]
5. Clinical use of FK 506 in liver transplantation.
Klintmalm GB
Transplant Proc; 1996 Apr; 28(2):974-6. PubMed ID: 8623484
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group.
Klintmalm GB; Goldstein R; Gonwa T; Wiesner RH; Krom RA; Shaw BW; Stratta R; Ascher NL; Roberts JW; Lake J
Transplant Proc; 1993 Feb; 25(1 Pt 1):641-3. PubMed ID: 7679828
[No Abstract] [Full Text] [Related]
7. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
8. Long-term comparison of tacrolimus versus cyclosporine in liver transplantation. The US FK Study Group.
Wiesner RH
Transplant Proc; 1998 Jun; 30(4):1399-400. PubMed ID: 9636565
[No Abstract] [Full Text] [Related]
9. Tacrolimus (FK 506) for rescue of chronic rejection following orthotopic liver transplantation.
Sher LS; Cosenza CA; Petrovic LM; Rojter S; Hoffman A; Lopez RR; Meehan M; Pan SH; Vierling J; Makowka L
Transplant Proc; 1996 Apr; 28(2):1011-3. PubMed ID: 8623212
[No Abstract] [Full Text] [Related]
10. The superior immunosuppressant according to diagnosis: FK 506 or cyclosporine A.
Mueller AR; Platz KP; Blumhardt G; Bechstein WO; Steinmüller T; Christe W; Hopf U; Lobeck H; Neuhaus P
Transplant Proc; 1995 Feb; 27(1):1117-20. PubMed ID: 7533359
[No Abstract] [Full Text] [Related]
11. FK 506 rescue therapy in liver transplant recipients with drug-resistant rejection.
Lewis WD; Jenkins RL; Burke PA; Winn KM; Shaffer D; Lopez R; Monaco AP
Transplant Proc; 1991 Dec; 23(6):2989-91. PubMed ID: 1721336
[No Abstract] [Full Text] [Related]
12. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
13. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
14. Bone loss after orthotopic liver transplantation: FK 506 versus cyclosporine.
Park KM; Hay JE; Lee SG; Lee YJ; Wiesner RH; Porayko MK; Krom RA
Transplant Proc; 1996 Jun; 28(3):1738-40. PubMed ID: 8658863
[No Abstract] [Full Text] [Related]
15. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
16. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival.
Jacob DA; Neumann UP; Bahra M; Langrehr JM; Neuhaus P
Transplant Proc; 2005 May; 37(4):1691-2. PubMed ID: 15919432
[TBL] [Abstract][Full Text] [Related]
17. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
18. Microemulsion cyclosporine with C2 monitoring and tacrolimus in liver transplantation with or without hepatitis C virus infection.
Jain A
Liver Transpl; 2006 Oct; 12(10):1452-4. PubMed ID: 17004248
[No Abstract] [Full Text] [Related]
19. Tacrolimus versus cyclosporin microemulsion in liver transplantation: results of a 3-month study.
Mühlbacher F;
Transplant Proc; 2001; 33(1-2):1339-40. PubMed ID: 11267317
[No Abstract] [Full Text] [Related]
20. Neurotoxicity of FK 506 in liver transplant recipients.
Frank B; Perdrizet GA; White HM; Marsh JW; Lemann W; Woodle ES
Transplant Proc; 1993 Apr; 25(2):1887-8. PubMed ID: 7682355
[No Abstract] [Full Text] [Related]
[Next] [New Search]
